ArticlePLoS neglected tropical diseases2016
Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2020Pooled it
- Hypercoagulability and vascular proinflammatory activation promote cardiac-cerebral fibrinogenesis in a rodent model of Chagas disease.Emerging microbes & infections · 2026Article
- Treatment with low-dose bicistronic immunotherapy mitigates parasite persistence and improves serological and cardiac outcomes in adult mice infected withEmerging microbes & infections · 2026Article
- Kinetics of Biomarkers for Therapeutic Assessment in Swiss Mice Infected with a VirulentPathogens (Basel, Switzerland) · 2026Article
- Host-Derived Molecules as Novel Chagas Disease Biomarkers: Hypercoagulability Markers and Extracellular Vesicles.Methods in molecular biology (Clifton, N.J.) · 2026Article
- A guide for the generation of repositories of clinical samples for research on Chagas disease.PLoS neglected tropical diseases · 2024Article
- Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins.Emerging microbes & infections · 2022Article
- A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease.Molecules (Basel, Switzerland) · 2022Article
- Sheltered in Stromal Tissue Cells,Pathogens (Basel, Switzerland) · 2022Article
- Platelets, Macrophages, and Thromboinflammation in Chagas Disease.Journal of inflammation research · 2022Review
- Article
- Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.Scientific reports · 2021Article
- Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation.Molecular and cellular biochemistry · 2021Article
- Fibronectin degradation as biomarker forParasitology · 2021Article
- COVID-19: Implications for People with Chagas Disease.Global heart · 2020Review
- Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.PLoS neglected tropical diseases · 2020Article
- Human acute Chagas disease: changes in factor VII, activated protein C and hepatic enzymes from patients of oral outbreaks in Pará State (Brazilian Amazon).Memorias do Instituto Oswaldo Cruz · 2020Article
- Impaired frequencies and function of platelets and tissue remodeling in chronic Chagas disease.PloS one · 2019Article
- Nucleotide and nucleoside involvement in immunomodulation in experimental Chagas disease.Molecular and cellular biochemistry · 2018Article
- Scientometrics analysis of research activity and collaboration patterns in Chagas cardiomyopathy.PLoS neglected tropical diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Thromboembolic events were described in patients with Chagas disease without cardiomyopathy. We aim to confirm if there is a hypercoagulable state in these patients and to determine if there is an early normalization of hemostasis factors after antiparasitic treatment. Ninety-nine individuals from Chagas disease-endemic areas were classified in two groups: G1, with T.cruzi infection (n = 56); G2, healthy individuals (n = 43). Twenty-four hemostasis factors were measured at baseline. G1 patients treated with benznidazole were followed for 36 months, recording clinical parameters and performance of conventional serology, chemiluminescent enzyme-linked immunosorbent assay (trypomastigote-derived glycosylphosphatidylinositol-anchored mucins), quantitative polymerase chain reaction, and hemostasis tests every 6-month visits. Prothrombin fragment 1+2 (F1+2) and endogenous thrombin potential (ETP) were abnormally expressed in 77% and 50% of infected patients at baseline but returned to and remained at normal levels shortly after treatment in 76% and 96% of cases, respectively. Plasmin-antiplasmin complexes (PAP) were altered before treatment in 32% of G1 patients but normalized in 94% of cases several months after treatment. None of the patients with normal F1+2 values during follow-up had a positive qRT-PCR result, but 3/24 patients (13%) with normal ETP values did. In a percentage of chronic T. cruzi infected patients treated with benznidazole, altered coagulation markers returned into normal levels. F1+2, ETP and PAP could be useful markers for assessing sustained response to benznidazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.